GT005

DRUG4 trials

Sponsors

Gyroscope Therapeutics Limited

Conditions

Age Related Macular Degeneration (AMD)Dry Age-related Macular DegenerationEye DiseasesGeographic AtrophyMacular AtrophyMacular DegenerationRetinal DegenerationRetinal Disease

Phase 1

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

TerminatedNCT03846193

Gyroscope Therapeutics LimitedDry Age-related Macular Degeneration, Eye Diseases, Geographic Atrophy +4

Start: 2018-12-17End: 2024-06-25Updated: 2026-01-28

Phase 2

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

TerminatedNCT04437368

Gyroscope Therapeutics LimitedDry Age-related Macular Degeneration

Start: 2019-04-26End: 2024-04-05Updated: 2026-01-27

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

TerminatedNCT04566445

Gyroscope Therapeutics LimitedDry Age-related Macular Degeneration

Start: 2020-09-28End: 2024-06-10Updated: 2026-01-28

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

Enrolling by invitationNCT05481827

Gyroscope Therapeutics LimitedAge Related Macular Degeneration (AMD)

Start: 2022-07-12End: 2028-06-02Target: 225Updated: 2024-03-22

Related Papers

Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells.

2021-03-1037 citations